- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01754987
A Study of Vitamin C in the Treatment of Liver Cancer to Determine if it is Safe and Effective
July 23, 2018 updated by: Thomas Jefferson University
Phase I/II Study of Intravenous Ascorbic Acid in Treatment of Metastatic Hepatocellular Carcinoma
This protocol is a phase I/II, study of ascorbic acid (AA) infusions combined with treatment with sorafenib versus treatment with sorafenib alone in subjects with metastatic hepatocellular carcinoma.
The phase I aspect will assess the safety and efficacy of the concurrent treatments and the phase II aspect will utilize CT (computer-tomography) scans to assess overall tumor response rate and evaluate disease progression
Study Overview
Status
Completed
Intervention / Treatment
Detailed Description
Intravenous Ascorbic Acid (Vitamin C) is a widely used alternative cancer treatment.
This trial will study an intravenous Vitamin C treatment for persons with liver cancer that has spread, who are also receiving Sorafenib (a standard cancer drug), to see whether the combination of Vitamin C and Sorafenib is safe and well tolerated.
Phase I will involve 6 persons who will receive the Vitamin C for 8 weeks to more specifically assess the safety of getting Vitamin C in combination with Sorafenib.
Phase II will be randomized to receive either Vitamin C plus Sorafenib or Sorafenib alone for 16 weeks.
If Vitamin C has a beneficial effect on tumour cells, patients may experience a regression of tumor or tumor markers.
Additional benefits include scans at no charge to the patient.
Study Type
Interventional
Enrollment (Actual)
5
Phase
- Phase 2
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19107
- Thomas Jefferson University
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Age > 18 years
- Metastatic hepatocellular carcinoma
- G6PD (glucose-6-phosphate dehydrogenase) status > lower limit of normal
- Eastern Cooperative Oncology Group (ECOG) performance status 0 to 2.
- Laboratory at baseline evaluation for inclusion in the study: creatinine ≤1.5X upper limit (if the creatinine is elevated, but ≤1.5X the ULN, a 24 hour creatinine clearance will be obtained); transaminase (AST/ALT) ≤2.0X upper limit of normal; bilirubin levels ≥ 2 mg/dL; ANC ≥1,500/mm3; Hemoglobin > 8g/dL; platelet ≥ 100,000/mm3
- Women of childbearing potential will confirm a negative pregnancy test and must practice effective contraception during the study.
- Willing and able to provide informed consent and participate in the study procedures.
Exclusion Criteria:
- Patients with evidence of a significant current psychiatric disorder that would prevent completion of the study as determined by the PI will not be allowed to participate.
- Co-morbid medical condition that would affect survival or tolerance as determined by the PI. This includes patients who have not fully recovered from toxicities associated with prior therapy. It also includes subjects who, as determined by the PI, are at risk of experiencing fluid overload (i.e., congestive heart failure).
- Patients who currently abuse alcohol or drugs.
- Patients with known glomerular filtration rate of <60ml/min or with nephrotic range proteinuria.
- Pregnant or lactating women
- Enrollment in active clinical trial/ experimental therapy or IND study within the prior 30 days.
- Contraindication for CT or PET/CT as per the PI.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NON_RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Ascorbic Acid + Sorafenib
Drug: Vitamin C Other Names: Ascorbic Acid, Ascorbate Dosage: Vitamin C : 100 grams (infusion) Phase I: 3x a week for 8 weeks Phase II: 3x a week for 16 weeks Sorafenib: taken daily (oral) |
Other Names:
|
OTHER: Sorafenib alone
Sorafenib: taken daily (oral)
|
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants That Experience Serious Adverse Events.
Time Frame: 16 weeks +/- 2 weeks
|
The primary aim is to assess whether or not (IV) Ascorbic Acid (AA) with sorafenib therapy is relatively safe and well-tolerated according to Common Terminology Criteria for Adverse Events (CTCAE)v4.0
|
16 weeks +/- 2 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall Tumor Response Rate
Time Frame: 16 weeks +/- 2 weeks
|
To utilize CT or PET/CT scans to assess overall tumor response rate (complete) in subjects with advanced metastatic hepatocellular cancer treated with the combination of ascorbic acid and sorafenib versus sorafenib alone.
|
16 weeks +/- 2 weeks
|
Mean Value Collected Using the Functional Assessment of Cancer Therapy-General (FACT-G) Quality Assessment Instrument
Time Frame: 16 weeks +/- 2 weeks
|
To evaluate quality of life using Functional Assessment of Cancer Therapy-General (FACT-G) quality assessment instrument.
The FACT-G questionnaire will be used to assess quality-of-life longitudinally.
Quality-of-life scores obtained from the FACT-G will be summarized at multiple time points.
Five-point scale from 0 (not at all) to 4 (very much)
|
16 weeks +/- 2 weeks
|
Number of Participants That Are Alive After 15 Weeks of Treatment.
Time Frame: 15 weeks+
|
To evaluate duration of tumor response and progression-free survival
|
15 weeks+
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
September 1, 2012
Primary Completion (ACTUAL)
January 1, 2016
Study Completion (ACTUAL)
January 1, 2016
Study Registration Dates
First Submitted
December 18, 2012
First Submitted That Met QC Criteria
December 18, 2012
First Posted (ESTIMATE)
December 21, 2012
Study Record Updates
Last Update Posted (ACTUAL)
August 23, 2018
Last Update Submitted That Met QC Criteria
July 23, 2018
Last Verified
July 1, 2018
More Information
Terms related to this study
Keywords
- Micronutrients
- Antineoplastic Agents
- Liver Cancer
- Physiological Effects of Drugs
- Integrative Medicine
- Pharmacologic Actions
- Complementary Medicine
- Therapeutic Uses
- Antineoplastic Agents, Phytogenic
- Radiation-Sensitizing Agents
- Molecular Mechanisms of Pharmacological Action
- Vitamins
- Growth Substances
- Protective Agents
- Malignant Tumor, Tumour
- Alternative Medicine Antioxidants
Additional Relevant MeSH Terms
- Digestive System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms by Site
- Adenocarcinoma
- Neoplasms, Glandular and Epithelial
- Digestive System Neoplasms
- Liver Diseases
- Carcinoma
- Carcinoma, Hepatocellular
- Liver Neoplasms
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antineoplastic Agents
- Protective Agents
- Micronutrients
- Protein Kinase Inhibitors
- Vitamins
- Antioxidants
- Sorafenib
- Ascorbic Acid
Other Study ID Numbers
- 12D.424
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Advanced Liver Cancer
-
Jiangsu Simcere Pharmaceutical Co., Ltd.UnknownAdvanced or Metastatic Gastric Cancer | Advanced or Metastatic CRC | Advanced or Metastatic Liver Cancer | Advanced or Metastatic Non Squamous NSCLCChina
-
M.D. Anderson Cancer CenterCompletedAdvanced Cancer | Liver CancerUnited States
-
Abbisko Therapeutics Co, LtdRecruiting
-
Guangxi Medical UniversityUnknown
-
Jiangsu HengRui Medicine Co., Ltd.CompletedAdvanced Biliary Tract Carcinoma | Advanced Primary Liver CancerChina
-
Benhealth Biopharmaceutical (Shenzhen) Co., Ltd.Beijing 302 HospitalUnknownAdvanced Liver CancerChina
-
Fuda Cancer Hospital, GuangzhouBenhealth Biopharmaceutical (Shenzhen) Co., Ltd.WithdrawnAdvanced Liver CancerChina
-
BeiJing Yijiayi Medicine Techonoloy Co., Ltd.Dalian Holley Kingkong Pharmaceutical Co., LtdUnknownAdvanced Primary Liver CancerChina
-
Shandong Public Health Clinical CenterImbioray (Hangzhou) Biomedicine Co., Ltd.Not yet recruitingAdvanced Primary Liver Cancer
-
BeiJing Yijiayi Medicine Techonoloy Co., Ltd.Dalian Holley Kingkong Pharmaceutical Co., LtdUnknown
Clinical Trials on Sorafenib
-
BayerAmgenCompleted
-
Ohio State University Comprehensive Cancer CenterBayerTerminated
-
Technical University of MunichCompleted
-
Ottawa Hospital Research InstituteBayerCompletedMetastatic Colorectal CancerCanada
-
British Columbia Cancer AgencyWithdrawnLocally Advanced Squamous Cell Carcinomas of the Head and Neck (SCCHN)Canada
-
Yiviva Inc.RecruitingAdvanced Hepatocellular CarcinomaUnited States, Taiwan, China, Hong Kong
-
National Cancer Institute (NCI)CompletedNon-Small-Cell Lung CarcinomaUnited States
-
Cancer Institute and Hospital, Chinese Academy...CompletedHepatocellular Carcinoma, Radiotherapy, SorafenibChina
-
Accelerated Community Oncology Research NetworkBayerTerminatedRenal Cell CarcinomaUnited States
-
China Medical University HospitalUnknown